May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Combined Photodynamic Therapy With Visudyne, Intravitreal Injection of Lucentis and Dexamethasone, and Oral Minocycline in the Treatment of Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • S. P. Chatterjee
    Ophthalmology, Kings College Hospital, London, United Kingdom
  • J. DaCosta
    Ophthalmology, Kings College Hospital, London, United Kingdom
  • T. Adewoyin
    Ophthalmology, Kings College Hospital, London, United Kingdom
  • V. Chong
    Ophthalmology, Kings College Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships  S.P. Chatterjee, None; J. DaCosta, None; T. Adewoyin, None; V. Chong, None.
  • Footnotes
    Support  Novartis provided Lucentis and research support
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 545. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. P. Chatterjee, J. DaCosta, T. Adewoyin, V. Chong; Combined Photodynamic Therapy With Visudyne, Intravitreal Injection of Lucentis and Dexamethasone, and Oral Minocycline in the Treatment of Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):545.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the safety and efficacy of combination therapy of PDT (reduced fluence), intravitreal Lucentis and dexamethasone, and oral minocycline in subfoveal neovascular AMD.

Methods: : Consecutive patients were treated with PDT (reduced fluence), intravitreal Lucentis and dexamethasone and oral minocycline at baseline. Monthly follow-up was performed. Re-treatment with Lucentis alone was indicated if best corrected vision was reduced by 5 letters and/or the central retinal thickness on OCT was increased by more than 100 microns.

Results: : Nineteen eyes of 19 patients have been enrolled. The mean age is 79.04 year (range 63 to 89). Fifteen patients included in the analysis have a mean follow-up of 3.9 months (range 3 to 5). The mean re-treatment rate is 1.1 (range 0 to 2). Twelve percent of patients have gained > 15 letters, 60% have gained vision and no patient has lost >15 letters to date. The central retinal thickness on OCT was reduced on average by 67.13 microns (p=0.012).

Conclusions: : This combination therapy appears to be safe and the visual outcome is comparable to monthly injection of Lucentis based on ANCHOR and MARINA study but with significantly fewer injections.

Clinical Trial: : www.controlled.trials.com CCT-NAPN-17287

Keywords: age-related macular degeneration • choroid: neovascularization • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×